Neurology Neuroimmunology & Neuroinflammation · 2024 · 37 citations · 8 references
Life SciencesImmunologyOncologyAutoimmunityCell TherapyImmunotherapyCell-based ImmunotherapyCell-mediated ImmunityCellular TherapyChimeric Antigen Receptor T-cell TherapyRelapsed DiseaseT Cell ActivationAllogeneic Car T-cell TherapyAutologous Car T-cell TherapyCar T Cell TrialsChimeric Antigen Receptor T Cell Combination TherapyMog Antibody DiseaseMog Antibody-associated DiseaseT-cell Therapy
OBJECTIVES: In MOG antibody-associated disease (MOGAD), relapse prevention and the treatment approach to refractory symptoms are unknown. We report a patient with refractory MOGAD treated with CD19-directed CAR T-cells. METHODS: CD19-directed CAR T-cells (ARI-0001) were produced in-house by lentiviral transduction of autologous fresh leukapheresis and infused after a conventional lymphodepleting regimen. RESULTS: B cells at day +7; reconstituted B cells at day +141 showing a naïve B-cell phenotype, and low or absent memory B cells and plasmablasts for 1 year. MOG-IgG titers have remained undetectable since CAR T-cell infusion. The patient had an early episode of left ON at day +29, when MOG-IgG was already negative, and since then he has remained free of relapses without immunotherapy for 1 year. DISCUSSION: This clinical case shows that CD19-directed CAR T-cell therapy is well-tolerated and is a potential treatment for patients with refractory MOGAD. CLASSIFICATION OF EVIDENCE: This provides Class IV evidence. It is a single observational study without controls.
8
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Andréas Mackensen, Fabian Müller, Dimitrios Mougiakakos et al. · Nature Medicine · 2022 · 999 citations